Results 1 to 10 of about 1,091 (176)

Oral and IV Varespladib Rescue Experiments in Juvenile Pigs with Weakness Induced by Australian and Papuan Oxyuranus scutellatus Venoms [PDF]

Toxins, 2023
Antivenom is currently the standard-of-care treatment for snakebite envenoming, but its efficacy is limited by treatment delays, availability, and in many cases, species specificity.
Lyndi L. Gilliam, John Gilliam, Stephen P. Samuel, Rebecca W. Carter, Jerry Ritchey, Tommaso Bulfone, José María Gutiérrez, David J. Williams, Daniela M. Durkin, Sally I. Stephens, Matthew R. Lewin   +10 more
doaj   +7 more sources

Feasibility study: Varespladib protects CD-1 mice from lethal doses of whole bee (Apis mellifera) venom [PDF]

Toxicon: X
Swarming Hymenoptera attacks can deliver high cumulative doses of venom resulting in death and life-threatening or chronically disabling injuries. Varespladib, a potent inhibitor of snake venom secretory PLA2 (sPLA2), is a relatively weak inhibitor of ...
James Hearth, Kaitlin Linne, Jerry Harrison, Hossein Zolfaghari, Matthew R. Lewin   +4 more
doaj   +6 more sources

In Vitro Efficacy of Antivenom and Varespladib in Neutralising Chinese Russell’s Viper (Daboia siamensis) Venom Toxicity [PDF]

Toxins, 2023
The venom of the Russell’s viper (Daboia siamensis) contains neurotoxic and myotoxic phospholipase A2 toxins which can cause irreversible damage to motor nerve terminals.
Mimi Lay, Qing Liang, Geoffrey K. Isbister, Wayne C. Hodgson   +3 more
doaj   +7 more sources

Varespladib attenuates Naja atra-induced acute liver injury via reversing Nrf2 signaling-mediated ferroptosis and mitochondrial dysfunction [PDF]

Redox Report
Objective: To investigate the protective effects of varespladib against Naja atra-induced acute liver injury (ALI) and to elucidate the toxic mechanism of snake venom phospholipase A2 (SVPLA2)-induced hepatic oxidative stress, with a particular focus on ...
Jiahao Liu, Linfeng Wang, Mengxia Xie, Wenjie Zhao, Jiaqi Sun, Yuji Jin, Meiling Liu, Jianqi Zhao, Lixia Cheng, Cheng Wen, Xiaowen Bi, Chunhong Huang   +11 more
doaj   +6 more sources

Anticoagulant Activity of Naja nigricollis Venom Is Mediated by Phospholipase A2 Toxins and Inhibited by Varespladib [PDF]

Toxins, 2021
Bites from elapid snakes typically result in neurotoxic symptoms in snakebite victims. Neurotoxins are, therefore, often the focus of research relating to understanding the pathogenesis of elapid bites.
Taline D. Kazandjian, Arif Arrahman, Kristina B. M. Still, Govert W. Somsen, Freek J. Vonk, Nicholas R. Casewell, Mark C. Wilkinson, Jeroen Kool   +7 more
doaj   +12 more sources

A Combined Bioassay and Nanofractionation Approach to Investigate the Anticoagulant Toxins of Mamba and Cobra Venoms and Their Inhibition by Varespladib [PDF]

Toxins, 2022
Envenomation by elapid snakes primarily results in neurotoxic symptoms and, consequently, are the primary focus of therapeutic research concerning such venoms. However, mounting evidence suggests these venoms can additionally cause coagulopathic symptoms,
Arif Arrahman, Taline D. Kazandjian, Kristina B. M. Still, Julien Slagboom, Govert W. Somsen, Freek J. Vonk, Nicholas R. Casewell, Jeroen Kool   +7 more
doaj   +12 more sources

Oral varespladib for the treatment of snakebite envenoming in India and the USA (BRAVO): a phase II randomised clinical trial [PDF]

BMJ Global Health
Introduction Snakebite envenoming (SBE) results in over 500 000 deaths or disabling injuries annually. Varespladib methyl, an oral inhibitor of secretory phospholipase A2, is a nearly ubiquitous component of snake venoms. We conducted a phase II clinical
Chanaveerappa Bammigatti, Timothy F Platts-Mills, Ashish Bhalla, Harish Kumar, Matthew R Lewin, Surendra Kumar, Charles J Gerardo, Rebecca W Carter, Farshad M Shirazi, Suneetha D Kotehal, Peter D Akpunonu, Richard B Schwartz, Neeraj Manikath, Partha P Mukherjee, Thomas C Arnold, Brian J Wolk, Sophia S Sheikh, Dawn R Sollee, David J Vearrier, Samuel J Francis, Adiel Aizenberg, Madhu K Ravikumar, Sujoy Sarkar, Taylor Haston, Andrew Micciche, Suraj C Oomman, Jeffery L Owen, Brandi A Ritter, Stephen P Samuel   +28 more
doaj   +5 more sources

The BRAVO Clinical Study Protocol: Oral Varespladib for Inhibition of Secretory Phospholipase A2 in the Treatment of Snakebite Envenoming [PDF]

Toxins, 2022
Introduction: Snakebite is an urgent, unmet global medical need causing significant morbidity and mortality worldwide. Varespladib is a potent inhibitor of venom secretory phospholipase A2 (sPLA2) that can be administered orally via its prodrug ...
Rebecca W. Carter, Charles J. Gerardo, Stephen P. Samuel, Surendra Kumar, Suneetha D. Kotehal, Partha P. Mukherjee, Farshad M. Shirazi, Peter D. Akpunonu, Chanaveerappa Bammigatti, Ashish Bhalla, Neeraj Manikath, Timothy F. Platts-Mills, Matthew R. Lewin   +12 more
doaj   +5 more sources

A Comparison of the Efficacy of Antivenoms and Varespladib against the In Vitro Pre-Synaptic Neurotoxicity of Thai and Javanese Russell’s Viper (Daboia spp.) Venoms [PDF]

Toxins
The heterogeneity in venom composition and potency in disparate Eastern Russell’s viper (Daboia siamensis) populations has repercussions for the efficacy of antivenoms. This is particularly pronounced in geographical areas in which the venom of the local
Mimi Lay, Wayne C. Hodgson
doaj   +5 more sources

Varespladib in the Treatment of Snakebite Envenoming: Development History and Preclinical Evidence Supporting Advancement to Clinical Trials in Patients Bitten by Venomous Snakes [PDF]

Toxins, 2022
The availability of effective, reliably accessible, and affordable treatments for snakebite envenoming is a critical and long unmet medical need. Recently, small, synthetic toxin-specific inhibitors with oral bioavailability used in conjunction with ...
Matthew R. Lewin, Rebecca W. Carter, Isabel A. Matteo, Stephen P. Samuel, Sunita Rao, Bryan G. Fry, Philip E. Bickler   +6 more
doaj   +5 more sources